All In Biotech

Drug Trial Radar · NCT04607421

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 841 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

841

Actual

Start

Dec 21, 2020

Primary completion

Mar 1, 2025

Study completion Jul 29, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.; Merck KGaA, Darmstadt, Germany; Eli Lilly and Company
First posted
Oct 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. Participants in this study will receive one of the following study treatments: * Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. * Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home. * Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home. This study is currently enrolling participants who will receive either encorafenib plus cetuximab with chemotherapy or chemotherapy alone. The study team will monitor how each participant responds to the study treatment for up to about 3 years.

Conditions

  • Neoplasms

Interventions

  • EncorafenibDrug

    75 mg capsules

  • CetuximabDrug

    Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial

  • OxaliplatinDrug

    Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial

  • IrinotecanDrug

    Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial

  • LeucovorinDrug

    Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial

  • 5-FUDrug

    Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial

  • CapecitabineDrug

    150 mg or 500 mg Tablet

  • BevacizumabDrug

    Optional Injection for intravenous use 100 mg/vial or 400 mg/vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SLI: Number of Participants With Dose Limiting Toxicity (DLTs)Time frame: Cycle 1 (28 days)
  2. Phase 3: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) for Arm B vs Arm C - FASTime frame: From date of randomization to earliest documentation of PD by BICR or death or censoring date, whichever occurred first (maximum up to 37.25 months)
  3. Phase 3: Objective Response Rate (ORR) as Assessed by BICR for Arm B vs Arm C - FAS ORR SubsetTime frame: From date of randomization to until documented PD by BICR, or start of subsequent anticancer therapy or death, whichever occurred first (maximum up to 24.71 months)
  4. Cohort 3: ORR as Assessed by BICR for Arm D vs Arm E - FASTime frame: From date of randomization until documented PD by BICR, or start of subsequent anticancer therapy or death, whichever occurred first (maximum up to 14.1 months)

Locations

274 sites in 29 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic in Arizona - Scottsdale

    Scottsdale, Arizona

  • Keck Hospital of USC

    Los Angeles, California

  • LAC & USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center/Investigational Drug Services

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Keck Hospital of USC Pasadena

    Pasadena, California

  • Mount Sinai Comprehensive Cancer Center, Aventura

    Aventura, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • BRCR Global

    Plantation, Florida

  • BRCR Medical Center Inc.

    Plantation, Florida

  • UChicago Medicine - River East

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • UChicago Medicine at Ingalls - Flossmoor

    Flossmoor, Illinois

  • UChicago Medicine Ingalls Memorial

    Harvey, Illinois

  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital

    New Lenox, Illinois

  • The University of Chicago Medicine Center for Advanced Care Orland Park

    Orland Park, Illinois

  • UChicago Medicine at Ingalls - Tinley Park

    Tinley Park, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Siteman Cancer Center - St Peters

    City of Saint Peters, Missouri

  • Siteman Cancer Center - West County

    Creve Coeur, Missouri

  • Siteman Cancer Center - North County

    Florissant, Missouri

  • Barnes- Jewish Hospital

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center - South County

    St Louis, Missouri

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • Oncology Hematology West PC dba Nebraska Cancer Specialists

    Papillion, Nebraska

  • Memorial Sloan Kettering Cancer Center - Basking Ridge

    Basking Ridge, New Jersey

  • Summit Medical Group

    Berkeley Heights, New Jersey

  • Summit Medical Group

    Florham Park, New Jersey

  • Memorial Sloan Kettering Cancer Center- Monmouth

    Middletown, New Jersey

  • Memorial Sloan Kettering Cancer Center- Bergen

    Montvale, New Jersey

  • Memorial Sloan Kettering Cancer Center Commack

    Commack, New York

  • Memorial Sloan Kettering Cancer Center - Westchester

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

Showing 40 of 274 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.